Skip to main content

Table 6 Comparison of survival outcomesin the COU-AA-302 study and our study

From: Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors

 

Median OS, months

Median PSA PFS, months

Median rPFS, months

Present study (AA plus prednisone group)

23.3

10.3

13.9

COU-AA-302 study

34.7

–

16.5

  1. Abbreviations: OS overall survival, PSA PFS PSA progression free survival, rPFS radiographic progression free survival, AA abiraterone acetate
Back to article page

BMC Urology

ISSN: 1471-2490

Contact us